Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FN8Y
|
|||
| Drug Name |
Heteroaromatic ring derivative 4
|
|||
| Synonyms |
PMID28447479-Compound-19
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG BEATTIE, David BAETTIG, Urs LEGRAND, Darren Mark LISTER, Andrew Stuart MCKENNA, Jeffrey PEARCE, David William SANDHAM, David Andrew STEWARD, Oliver Ross THOMSON, Christopher
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H33F3N8O
|
|||
| Canonical SMILES |
CC1=NN(N=N1)CC2=C(C=CC(=C2)C(F)(F)F)CCC(=O)N3CCC(CC3)CCCCCC4=NNN=C4
|
|||
| InChI |
1S/C25H33F3N8O/c1-18-30-34-36(32-18)17-21-15-22(25(26,27)28)9-7-20(21)8-10-24(37)35-13-11-19(12-14-35)5-3-2-4-6-23-16-29-33-31-23/h7,9,15-16,19H,2-6,8,10-14,17H2,1H3,(H,29,31,33)
|
|||
| InChIKey |
KVDZWWLIQHBBCT-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular lysophospholipase D (E-NPP2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Extracellular lysophospholipase D (E-NPP2) | Target's Patent Info | [1] | |
| KEGG Pathway | Ether lipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.